Picture loading failed.

Anti-CD40 therapeutic antibody (Pre-made Sotigalimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Sotigalimab is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. Sotigalimab targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-529-1mg 1mg 3090
GMP-Bios-ab-529-10mg 10mg 21890
GMP-Bios-ab-529-100mg 100mg 148000
GMP-Bios-ab-529-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD40 therapeutic antibody (Pre-made Sotigalimab biosimilar,Whole mAb)
INN Name Sotigalimab
TargetCD40
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommended2021
CompaniesApexigen
Conditions Approvedna
Conditions ActivePancreatic cancer;Metastatic cancer;Non-small cell lung cancer;Renal cell carcinoma;Gastric adenocarcinoma;Soft-tissue sarcoma;Esophageal carcinoma;Rectal cancer;Malignant melanoma
Conditions DiscontinuedBrain cancer;Glioma;Solid tumours
Development Techna